BiotechTube

PF-02545920 + PF-02545920

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease

Trial Timeline

Sep 1, 2014 → Oct 1, 2016

NCT ID
NCT02197130

About PF-02545920 + PF-02545920

PF-02545920 + PF-02545920 is a phase 2 stage product being developed by Pfizer for Huntington's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02197130. Target conditions include Huntington's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02197130Phase 2Completed
NCT01244880Phase 1Terminated

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
AFQ056 + PlaceboNovartisPhase 2
52
RO7234292 (RG6042)RochePhase 2
52
RG6496 + PlaceboRochePhase 1
33
20 mg BID of PF-02545920PfizerPhase 2
51
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
51
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
30
TetrabenazineLundbeckApproved
82
BN82451B + PlaceboIpsenPhase 2
49
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
38
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
36
WVE-120101 + PlaceboWaVe Life SciencesPhase 1/2
36
SAGE-718Supernus PharmaceuticalsPhase 3
72
SAGE-718 + PlaceboSupernus PharmaceuticalsPhase 2
47
OMS643762 + PlaceboOmeros CorporationPhase 2
47
VX15/2503 + PlaceboVaccinexPhase 2
44

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84